Biological medicines often represent the cutting-edge of biomedical research and have revolutionized the treatment of a variety of medical illnesses and conditions that presently have no other treatments available. A biosimilar product is exactly what its name implies — it is a biologic that is “similar” to another biologic drug already approved by the FDA. To help increase awareness and understanding of the important scientific, regulatory and reimbursement policies for these medicines, PhRMA is excited to launch a new section of our website today that provides educational resources on these topics.
Within the new website section, you can find the following information:
- How biologics and biosimilars work;
- What data protection measures are in place to promote research and development of these medicines; and,
- How science-based regulatory policies protect patient safety and facilitate health care provider and patient choice.
Additionally, a number of downloadable fact sheets and infographics are available on more in-depth biologics and biosimilars topics. As the regulatory environment surrounding these medicines continues to evolve, PhRMA will develop and offer additional resources on the page that provide key facts on these milestones.
Our goal is to create a comprehensive source of information on biologics and biosimilars, so that we can help improve awareness, science and evidence-based decision-making and patient choice.
To access the new biologics and biosimilars web page, go to: www.PhRMA.org/Biosimilars
Andrew Powaleny Andrew Powaleny is Director of Public Affairs at PhRMA. Before joining PhRMA in 2015, he worked at the House Energy and Commerce Committee and later as a communications consultant. Andrew came to Washington, D.C. via Connecticut and proudly sings with the Gay Men’s Chorus of Washington, runs with the DC Front Runners and serves on the Alumni Council for The Fund for American Studies. He is also a member of the National Lesbian Gay Journalists Association.